Clinical Trial Update: Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating famitinib plus anti-PD1 therapy for advanced renal cell carcinoma, urothelial carcinoma, and gynecologic cancers such as cervical, ovar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer Recurrent
• Renal Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Anti-PD1 therapy
• Famitinib (Famitinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Renal Cell Carcinoma, Urothelial Carcinoma | Phase 2 | Status: UNKNOWN